MucE Expression Detection for Early Pseudomonas Biofilm Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting the conversion of Pseudomonas aeruginosa to the mucoid state in cystic fibrosis patients are inadequate for early detection, leading to delayed aggressive therapy and further disease deterioration, as existing technologies struggle to accurately and rapidly identify the transition before the emergence of mucoid colony morphology on growth plates.
Innovation Solution
The identification and use of mucE, a positive regulator of alginate production in Pseudomonas aeruginosa, along with molecular probes and antibodies, enable early detection of mucoid conversion through methods like Northern blot, RT-PCR, and real-time RT-PCR, allowing for the development of diagnostic kits and the prevention of biofilm formation by inhibiting mucE expression or activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional detection methods are used, then detection simplicity is maintained, but detection precision and early detection capability deteriorate
Solution Approach 1:
The patent detects mucE gene expression levels before the actual conversion to mucoid phenotype occurs. By monitoring the positive regulator's activity in advance, the system enables early detection and intervention before the bacterial strain becomes mucoid and forms biofilms, thereby improving detection precision while maintaining manageable complexity through targeted molecular assays.
Solution Approach 2:
The patent uses mucE gene expression as an intermediary marker to detect the transition to mucoid state. Instead of directly detecting the mucoid phenotype or biofilm formation, the system measures the expression level of the positive regulator mucE, which serves as an early indicator that precedes the actual conversion, thereby enabling earlier and more precise detection.
2Loss of time
If early detection methods are implemented, then treatment timing is improved, but detection complexity increases
Solution Approach 1:
By detecting mucE expression levels before the mucoid conversion is complete, the system reduces the detection time window. The method identifies the transition at its earliest molecular stage through RT-PCR or Northern blot analysis of mucE transcripts, enabling clinicians to initiate aggressive therapy before the infection becomes chronic and difficult to treat.
Solution Approach 2:
The patent changes the detection parameter from phenotypic observation (colony morphology on growth plates) to molecular parameter measurement (mucE gene expression levels). This parameter shift enables detection at an earlier stage when only molecular changes have occurred, not yet visible as phenotypic changes, thereby reducing detection time despite increased analytical complexity.
3Reliability
If mucoid conversion is detected late, then treatment effectiveness deteriorates, but detection method simplicity is maintained
Solution Approach 1:
The system performs detection at the molecular level before phenotypic conversion is complete. By measuring mucE expression levels in clinical samples, the method identifies impending mucoid conversion early, allowing aggressive antibiotic therapy to be initiated while the infection is still treatable, thereby maintaining high treatment effectiveness despite the increased difficulty of molecular detection compared to simple phenotypic observation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables early detection of mucoid conversion in Pseudomonas aeruginosa, facilitating timely aggressive antibiotic therapy and preventing further disease deterioration by identifying increased mucE messenger RNA levels, which correlates with the onset of mucoidy, thereby delaying the progression of chronic infection.
Implementation Method 1
contacting messenger RNA from the cell sample with a mucE nucleic acid segment, and detecting the presence of increased hybridized complexes
Implementation Method 2
reacting a sample suspected of containing Pseudomonas aeruginosa with a MucE monoclonal antibody or fragment thereof, separating the sample from unbound antibody, and detecting the presence of immune complexes formed between the monoclonal antibody and MucE
Data Source
AI summary
Compositions and methods for detecting and controlling the conversion to mucoidy in Pseudomonas aeruginosa are disclosed. The present invention provides for detecting the switch from nonmucoid to mucoid state of P. aeruginosa by measuring mucE expression or MucE protein levels. The interaction between MucE and AlgW controls the switch to mucoidy in wild type P. aeruginosa. Also disclosed is an alginate biosynthesis heterologous expression system for use in screening candidate substances that inhibit conversion to mucoidy.